

MONDAY, SEPTEMBER 16, 2019 | Symposium 9 | 1:30 – 3:00 PM

Latest Advances in Treatment, Prophylaxis & Pharmacogenomics of HIV

PATIENT-CENTRIC TRACK

Offers both CME & CPE Credit

UAN #0238-0000-19-009-L01-P

ACPE – 1.5 CONTACT HOURS/KNOWLEDGE-BASED

CHAIR:

Sam Harirforoosh, PharmD, PhD, Associate Professor, East Tennessee State Univ Coll of Pharmacy, Pharmaceutical Sciences

TARGET AUDIENCE:

This Symposium will be useful for distilling information, both evidence-based and theoretical, to the target audience of clinicians, pharmacists and scientists in practice, as well as in clinical research and drug development environments.

GOALS & OBJECTIVES:

Following the completion of this activity, the learner will be able to:

1. Discuss current treatments of HIV infection;
2. Demonstrate the role of genetics in HIV infection treatment;
3. Explain strategies for the prevention of HIV infection;
4. Discuss the regulatory issues for developing new therapies for the treatment and prevention of HIV-1 infection.

1:30 – 1:50 PM

Challenges of HIV Infection Treatment

Susan E. Cohn, MD, MPH, Professor of Medicine, Northwestern Univ Feinberg School of Medicine

1:50 – 2:10 PM

Pharmacogenetics of HIV Drugs: A Focus on Integrase Inhibitors

Sam Harirforoosh, PharmD, PhD, Associate Professor, East Tennessee State Univ Coll of Pharmacy, Pharmaceutical Sciences

2:10 – 2:30 PM

Development of HIV Pre-exposure Prophylaxis that Provides Essential CHOICE for Populations at Risk

Craig W. Hendrix, MD, Wellcome Professor & Director, Johns Hopkins Univ School of Medicine, Clinical Pharmacology

2:30 – 2:50 PM

Regulatory Perspectives on the Development of Products for the Treatment & Prevention of HIV-1 Infection

Kimberly A. Struble, PharmD, US Food & Drug Administration, CDER, Antiviral Products

2:50 – 3:00 PM

Faculty Panel Discussion, Questions & Answers, Learner Feedback & Evaluations